Subscribe to RSS
DOI: 10.1055/s-0031-1296435
Study on the Pharmacokinetics of Synthetic Genistein after Multiple Oral Intake in Post-menopausal Women
Publication History
Publication Date:
13 December 2011 (online)


Abstract
Genistein (CAS 446-72-0), an isoflavone and phytoestrogen predominantly found in soy, is considered a promising natural bioactive to prevent post-menopausal bone loss.
geniVida™ (previously Bonistein®), a novel product containing of min. 98.5% synthetic genistein aglycone, was investigated in 12 healthy post-menopausal women to assess the safety and tolerabil-ity as well as to obtain pharmacokinetic data after 7 days of repeated intakes. 24 h pharmacokinetic profiles were determined after the first oral dose and after 7 days repeated intakes of 30 mg of the test formulation. Plasma genistein (aglycone) and its conjugates were determined by a standardised LC/MS analytical method using D4-genistein as the internal standard.
The plasma-concentration time profiles for conjugated genistein showed a fast, monophasic one-peak course until Tmax (5.9 h (first dose), 5.3 h (steady state (SS)); Cmax (456.8 ng/ml (first dose), 498.5 ng/ml (SS)). Elimination half-lives (t1/2) were calculated to be 10.8 h (first dose) and 8.2 h (SS), respectively. Determination of AUC(0–inf.) (first dose) was good with a low percentage of extrapolation (3 949.1 h ng/ml). AUC(0–24h) at SS was 5 923.3 h ng/ml. Steady state was reached after 4 to 5 days and no relevant accumulation occurred (R = 1.02).
The test formulation was safe and very well tolerated.